Concepedia

Publication | Closed Access

A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)

DOI

176

Citations

0

References

1996

Year

Daniel S. Stein, Douglas G. Fish, John A. Bilello, Sandra L. Preston, Gisele L. Martineau, George L. Drusano
AIDS

Abstract

MK-639 appears to have significant dose-related antiviral activity and is well tolerated.